TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) insider Tamer I. Khayal sold 5,558 shares of the firm’s stock in a transaction on Friday, January 20th. The stock was sold at an average price of $65.21, for a total value of $362,437.18. Following the transaction, the insider now owns 1,300 shares in the company, valued at $84,773. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
TransMedics Group Stock Up 5.1 %
Shares of TMDX stock opened at $64.33 on Friday. TransMedics Group, Inc. has a 1-year low of $10.00 and a 1-year high of $65.68. The stock’s fifty day moving average price is $59.22 and its 200 day moving average price is $49.80. The company has a debt-to-equity ratio of 0.31, a current ratio of 12.11 and a quick ratio of 11.21. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -42.89 and a beta of 1.57.
TransMedics Group (NASDAQ:TMDX – Get Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.15. TransMedics Group had a negative return on equity of 46.03% and a negative net margin of 58.78%. The firm had revenue of $25.68 million for the quarter, compared to the consensus estimate of $18.96 million. On average, research analysts expect that TransMedics Group, Inc. will post -1.3 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several research firms have commented on TMDX. Canaccord Genuity Group raised their price objective on TransMedics Group from $58.00 to $63.00 and gave the stock a “buy” rating in a report on Friday, November 4th. Morgan Stanley lifted their price target on TransMedics Group from $54.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, January 6th. Finally, Cowen lifted their price target on TransMedics Group from $60.00 to $70.00 in a report on Friday, December 16th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $53.29.
About TransMedics Group
TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
- Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.